Evaluation of the immune response elicited by multi-antigenic DNA vaccine expressing SAG1, ROP2 and GRA2 against Toxoplasma gondii

Parasitology International

Volumn 57, Issue 4, 2008, Pages 424-429

  Xue, Mingfu ^a   He, Shenyi ^a   Cui, Yuling ^a   Yao, Yuan ^a   Wang, Huaxin ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

GRA2; IL 12; ROP2; SAG1; Toxoplasma gondii

Indexed keywords

CYTOKINE; DENSE GRANULE ANTIGEN 2; DNA VACCINE; HYBRID PROTEIN; INTERLEUKIN 12; PHOSPHATE BUFFERED SALINE; PLASMID DNA; RHOPTRY PROTEIN 2; SURFACE ANTIGEN 1; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN EXPRESSION; ANTIGENICITY; ARTICLE; CELL ASSAY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENE EXPRESSION; HELPER CELL; IMMUNE RESPONSE; IMMUNOASSAY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARASITE IMMUNITY; PLASMID; PRIORITY JOURNAL; RECOMBINANT PLASMID; SURVIVAL TIME; TH1 CELL; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; FEMALE; IMMUNIZATION; INTERLEUKIN-12; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; PLASMIDS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; SPECIFIC PATHOGEN-FREE ORGANISMS; TH1 CELLS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, DNA;

AVES; MAMMALIA; MUS; TOXOPLASMA GONDII;

EID: 53049100142     PISSN: 13835769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parint.2008.05.001     Document Type: Article

References (49)

1. Dunn D., Wallon M., Peyron F., Petersen E., Peckham C., and Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling. Lancet 353 (1999) 1829-1833
2. Petersen E., Pollak A., and Reiter-Owona I. Recent trends in research on congenital toxoplasmosis. Int J Parasitol 31 (2001) 115-144
3. Mamidi A., DeSimone J.A., and Pomerantz R.J. Central nervous system infections in individuals with HIV-1 infection. J Neurovirology 8 (2002) 158-167
4. Fayer R., Dubey J.P., and Lindsay D.S. Zoonotic protozoa: from land to sea. Trends Parasitol 20 (2004) 531-536
5. Saavedra R., Becerril M.A., Dubeaux C., Lippens R., De Vos M.J., Herion P., et al. Epitopes recognized by human T lymphocytes in the ROP2 protein antigen of Toxoplasma gondii. Infect Immun 64 (1996) 3858-3862
6. Vercammen M., Scorza T., Huygen K., De Braekeleer J., Diet R., Jacobs D., et al. DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 68 (2000) 38-45
7. Mevelec M.N., Bout D., Desolme B., Marchand H., Magne R., Bruneel O., et al. Evaluation of protective effect of DNA vaccination with genes encoding antigens GRA4 and SAG1 associated with GM-CSF plasmid, against acute, chronical and congenital toxoplasmosis in mice. Vaccine 23 (2005) 4489-4499
8. Windeck T., and Gross U. Toxoplasma gondii strain-specific transcript levels of SAG1 and their association with virulence. Parasitol Res 82 (1996) 715-719
9. Lunden A. Immune response in sheep after immunization with Toxoplasma gondii antigens incorporated into iscoms. Vet Parasitol 56 (1995) 23-35
10. Nielsen H.V., Lauemoller S.L., Christiansen L., Buus S., Fomsgaard A., and Petersen E. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 67 (1999) 6356-6363
11. Liu K.Y., Zhang D.B., Wei Q.K., Li J., Li G.P., and Yu J.Z. Biological role of surface Toxoplasma gondii antigen in development of vaccine. World J Gastroenterol 12 (2006) 2363-2368
12. Siachoque H., Guzman F., Burqos J., Patarroyo M.E., and Gomez Marin J.E. Toxoplasma gondii: immunogenicity and protection by SAG1 peptides in a murine model. Exp Parasitol 114 (2006) 62-65
13. Dubey J.P. Advances in the life cycle of Toxoplasma gondii. Int J Parasitol 28 (1998) 1019-1024
14. Alexander J., Jebbari H., Bluethmann H., Satoskar A., and Roberts C.W. Immunological control of Toxoplasma gondii and appropriate vaccine design. Curr Top Microbiol Immunol 219 (1996) 183-195
15. Saavedra R., De Meuter F., Decourt J.L., and Herion P. Human T-cell clone identifies a potentially protective 54-kDa protein antigen of Toxoplasma gondii cloned and expressed in Escherichia coli. J Immunol 147 (1991) 1975-1982
16. Herion P., Hernandez-Pando R., Dubremetz J.F., and Saavedra R. Subcellular localization of the 54-kDa antigen of Toxoplasma gondii. J Parasitol 79 (1993) 216-222
17. Sadak A., Taghy Z., Fortier B., and Dubremetz J.F. Characterization of a family of rhoptry proteins of Toxoplasma gondii. Mol biochem parasitol 29 (1998) 203-211
18. Nigro M., Martin V., Kaufer F., Carral L., Angel S.O., and Pszenny V. High level of expression of the Toxoplasma gondii-recombinant Rop2 protein in Escherichia coli as a soluble form for optimal use in diagnosis. Mol Biotechnol 18 (2001) 269-273
19. Mishima M., Xuan X., Yokoyama N., Igarashi I., Fujisaki K., Nagasawa H., et al. Recombinant feline herpesvirus type 1 expressing Toxoplasma gondii ROP2 antigen inducible protective immunity in cats. Parasitol Res 88 (2002) 144-149
20. Chen G., Guo H., Lu F., and Zheng H. Construction of a recombinant plasmid harbouring the rhoptry protein 1 gene of Toxoplasma gondii and preliminary observations on DNA immunity. Chin Med J (Engl) 114 (2001) 837-840
21. Echeverria P.C., de Miguel N., Costas M., and Angel S.O. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine 24 (2006) 4102-4110
22. Cesbron-Delauw M.F. Dense-granule organelles of Toxoplasma gondii: their role in the host-parasite relationship. Parasitol Today 10 (1994) 293-296
23. Murray A., Mercier C., Decoster A., Lecordier L., Capron A., and Cesbron-Delauw M.F. Multiple B-cell epitopes in a recombinant GRA2 secreted antigen of Toxoplasma gondii. Appl Parasitol 34 (1993) 235-244
24. Golkar M., Rafati S., Abdel-Latif M.S., Brenier-Pinchart M.P., Fricker-Hidalgo H., Sima B.K., et al. The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn Microbiol Infect Dis 58 (2007) 419-426
25. Prigione I., Facchetti P., Lecordier L., Deslee D., Chiesa S., Cesbron-Delauw M.F., et al. T cell clones raised from chronically infected healthy humans by stimulation with Toxoplasma gondii excretory-secretory antigens cross-react with live tachyzoites: characterization of the fine antigenic specificity of the clones and implications for vaccine development. J Immunol 164 (2000) 3741-3748
26. Cesbron-Delauw M.F., Lecordier L., and Mercier C. Role of secretory dense granule organelles in the pathogenesis of toxoplasmosis. Curr Top Microbiol Immunol 219 (1996) 59-65
27. Zenner L., Estaquier J., Darcy F., Maes P., Capron A., and Cesbron-Delauw M.F. Protective immunity in the rat model of congenital toxoplasmosis and the potential of excreted-secreted antigens as vaccine components. Parasite Immunol 21 (1999) 261-272
28. Zhou H., Gu Q., Zhao Q., Zhang J., Cong H., Li Y., et al. Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris. Parasitol Res 100 (2007) 829-835
29. Zhang J., He S., Jiang H., Yang T., Cong H., Zhou H., et al. Evaluation of the immune response induced by multi-antigenic DNA vaccine encoding SAG1 and ROP2 of Toxoplasma gondii and the adjuvant properties of murine interleukin-12 plasmid in BALB/c mice. Parasitol Res 101 (2007) 331-338
30. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 70 (1998) 83-243
31. Gazzinelli R.T., Wysoka M., Hayashi S., Denkers E.Y., Hieny S., Caspan P., et al. Parasite-induced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J Immunol 153 (1994) 2533-2543
32. Scott P., and Trinchieri G. The role of natural killer cells in host-parasite interactions. Curr Opin Immunol 7 (1995) 34-40
33. Fachado A., Rodriguez A., Angel S.O., Pinto D.C., Vila I., Acosta A., et al. Protective effect of a naked DNA vaccine cocktail against lethal toxoplasmosis in mice. Vaccine 21 (2003) 1327-1335
34. Bunnell B.A., and Morgan R.A. Gene therapy for infectious diseases. Clin Microbiol Rev 11 (1998) 42-56
35. Robinson H.L. Nucleic acid vaccines: an overview. Vaccine 15 (1997) 785-787
36. Gurunathan S., Wu C.Y., Freidag B.L., and Seder R.A. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 12 4 (2000) 442-447
37. Angus C.W., Klivington-Evans D., Dubey J.P., and Kovacs J.A. Immunization with a DNA plasmid encoding the SAG1 (SAG1) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 181 (2000) 317-324
38. Golkar M., Shokrgozar M.A., Rafati S., Musset K., Assmar M., Sadaie R., et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 25 (2007) 4301-4311
39. Jongert E., De Craeye S., Dewit J., and Huygen K. GRA7 provides protective immunity in cocktail DNA vaccines against Toxoplasma gondii. Parasite Immunol 29 (2007) 445-453
40. Lowrie D.B., Tascon R.E., Bonato V.L., Lima V.M., Faccioli L.H., Stavropoulos E., et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 400 (1999) 269-271
41. Vossenkämper A., Struck D., Alvarado-Esquivel C., Went T., Takeda K., Akira S., et al. Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii, but IL-12 is dominant over IL-18 in parasite control. Eur J Immunol 34 (2004) 3197-3207
42. Khan I.A., Matsuura T., and Kasper L.H. Interleukin-12 enhances murine survival against acute toxoplasmosis. Infect Immun 62 (1994) 1639-1642
43. Letscher-Bru V., Villard O., Risse B., Zauke M., Klein J.P., and Kien T.T. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin-12 against toxoplasmosis in mice. Infect Immun 66 (1998) 4503-4506
44. Gherardi M.M., Ramirez J.C., and Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccine virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 74 (2000) 6278-6286
45. Mackova J., Kutinova L., Hainz P., Krystofova J., Sroller V., Otahal P., et al. Adjuvant effect of dendritic cells transduced with recombinant vaccine virus expressing HPV16-E7 is inhibited by co-expression of IL-12. Int J Oncol 24 (2004) 1581-1588
46. Manetti R., Parronchi P., Giudizi M.G., Piccinni M.P., Maggi E., Trinchieri G., et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177 (1993) 1199-1204
47. Petersen E., Nielsen H.V., Christiansen L., and Spenter J. Immunization with E. coli produced recombinant SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 16 (1998) 1283-1289
48. Klinman D.M., Yamshchikov G., and Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 158 (1997) 3635-3639
49. Krieg A.M., Yi A.K., Schorr J., and Davis H.L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol 6 (1998) 23-27